Traditional biomarkers complemented with genomic biomarkers as key drug development decision tools in order to identify people who may benefit or be at risk through treatment using a particular drug. The promise of these biomarkers lies in the potential to identify sources of inter-individual variability in drug response to maximize effectiveness and minimize risk.
